A Phase 2B, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating The Safety And Efficacy Of GS-6624, A Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) In Subjects With Primary Sclerosing Cholangitis (PSC)
Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active
This is a Phase 2b dose-ranging, randomized, double-blind, placebo-controlled clinical trial designed to assess the efficacy and safety of simtuzumab in subjects with PSC. Simtuzumab (GS-6624) is a humanized lgG4 monoclonal antibody against LOXL2. It is hypothesized that the inhibition of LOXL2 can prevent the progression of, and possibly reverse, fibrosis in subjects with ongoing liver disease.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.